文章核心观点 - AbbVie的药物Tepkinly(epcoritamab)获得欧洲药品管理局(EMA)的CHMP委员会的正面意见,建议批准其用于治疗复发/难治性滤泡性淋巴瘤(R/R FL)的扩展适应症[1][2][6] - 如果获批,Tepkinly将成为欧盟首个获批用于治疗R/R FL和R/R DLBCL的双特异性抗体单药疗法[4] - AbbVie与Genmab合作开发Epkinly/Tepkinly,双方在美国和日本分担商业责任,AbbVie负责全球商业化[7][8] - AbbVie在2024年第一季度从Epkinly和Tepkinly的收益中获得2700万美元[9] - AbbVie和Genmab正在评估Epkinly作为单药和联合用药在多种血液肿瘤适应症中的疗效[10] 行业相关 - 滤泡性淋巴瘤(FL)是最常见的一种慢性非霍奇金淋巴瘤,而弥漫大B细胞淋巴瘤(DLBCL)是最常见的一种急性非霍奇金淋巴瘤[5] - 默克公司的肺动脉高压药物Winrevair获得CHMP的正面意见,有望成为欧洲首个激活素信号抑制剂疗法[11] - 强生公司的Balversa获得CHMP的正面意见,用于治疗FGFR基因改变的晚期或转移性膀胱癌[12]

As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive Chairman Robert A. Michael Joins AbbVie Board of Directors NORTH CHICAGO, Ill., July 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that Robert A. Michael has assumed the role of chief executive officer (CEO) and has joined AbbVie's Board of Directors, effective today. As previously announced, Mr. Michael succeeds Richard A. Gonzalez, who has served as CEO since the company's inception in 2013. M ...

These stocks could be ideal for investors in their golden years. Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retirees can buy and hold forever. Here's why they picked AbbVie (ABBV 1.50%), Gilead Sciences (GILD -0.32%), and Johnson & Johnson (JNJ 0.25%). A Dividend King poised for growth Keith Spe ...

AbbVie (ABBV) announced that it has acquired Celsius Therapeutics, a private biotech making novel therapies for treating inflammatory bowel diseases (“IBD”). The acquisition will add Celsius Therapeutics’ lead pipeline candidate, CEL383, to AbbVie’s pipeline. CEL383 is a potential first-in-class TREM1 inhibitor, which has completed phase I study in IBD conditions. AbbVie will pursue further development of CEL383. TREM1 has been identified as a key gene involved in inflammation pathways associated with IBD. ...

If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapy Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 study NORTH CHICAGO, Ill., June 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA ...

AbbVie (ABBV) announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular lymphoma (FL). The drug has been developed in partnership with Genmab (GMAB) . The FDA approved Epkinlyunder the accelerated pathway to treat adults with relapsed or refractory (R/R) FL after two or more lines of therapies. The agency initially granted accelerated approval to the drug last year to treat patients with R/R diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lympho ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this drugmaker have returned +10.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 5.2% over this period. Now the key question is: Where could the stock be headed in the near term? Althoug ...

Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill., June 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first- in-class anti-TREM1 antib ...

Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and Products, Increasing Affordability of Treatments with Flexible Payment Options IRVINE, Calif., June 27, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today debuted Allē Payment Plans, powered by Cherry. By giving consumers the power to pay over-time for aesthetic treatments and produ ...

Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover, develop and commercialize new medicines targeting novel G protein-coupled receptor (GPCR) targets associ ...